Life-threatening hypophosphataemia in a cirrhotic patient with jaundice by Moutzouri, Elisavet et al.
Life-threatening hypophosphataemia in a cirrhotic patient
with jaundice
Elisavet Moutzouri, Evangelos N. Liberopoulos, Moses Elisaf
Abstract
We report the case of a 51-year-old patient with a history of liver cirrhosis, who
presented with jaundice (total bilirubin 50 mg/dl [855 µmol/l], direct bilirubin
20 mg/dl [342 µmol/l]) and life-threatening hypophosphataemia (serum
phosphate 0.5 mg/dl [0.16 mmol/l]), accompanied by inappropriate phosphaturia.
The patient also manifested hypouricaemia (serum uric acid 1.7 mg/dl
[101 µmol/l]) with renal uric acid wasting and renal glycosuria. This generalized
proximal tubular defect may occasionally be seen in deeply jaundiced patients.
Therefore, serum phosphate levels should be closely monitored in these patients.
K Ke ey y   w wo or rd ds s: :   hypophosphataemia, jaundice, cirrhosis, hepatitis.
Introduction
Normal serum phosphate ranges from 2.5 mg/dl to 4.5 mg/dl (0.80-
1.45 mmol/l). Hypophosphataemia is classified as moderate when serum
phosphate is 1.0-2.5 mg/dl (0.32-0.80 mmol/l) and severe when < 1.0 mg/dl
(< 0.32 mmol/l). Hypophosphataemia is observed in 0.25-2.15% of hospital
admissions, while severe hypophosphataemia affects 0.43% of hospitalized
patients [1].
Maintaining normal phosphate concentrations is essential for optimal
cellular function. Hypophosphataemia, especially when it is severe, may
result in serious complications, such as rhabdomyolysis, haemolysis, and
respiratory  and  cardiac  failure.  Clinical  manifestations  are  usually
encountered when serum phosphate concentration falls below 1 mg/dl
(0.32 mmol/l) [1].
Decreased uric acid levels have been occasionally described in jaundiced
patients [2]. However, jaundice may also lead to a more generalized
proximal tubular dysfunction mimicking Fanconi’s syndrome [3].
Herein we describe the case of a jaundiced patient with liver cirrhosis
who developed life-threatening hypophosphataemia with inappropriate
phosphaturia accompanied by hypouricaemia and glycosuria mimicking
Fanconi’s syndrome. The patient gave informed consent for publishing his
case in the medical literature.
Case report
A 51-year-old man was admitted to our hospital because of abdominal
distention and jaundice of recent onset. He had been diagnosed with
C Co or rr re es sp po on nd di in ng g   a au ut th ho or r: :
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P Pa ar ra am me et te er rs s R Re es su ul lt ts s N No or rm ma al l   l li im mi it ts s   
( (c co on nv ve en nt ti io on na al l   u un ni it ts s) )
BMI [kg/m2] 17 18.5-24.9
TBIL [mg/dl]  50  0.2-1.4
[µmol/l] (855)
DBIL [mg/dl]  20 0.0-0.4
[µmol/l] (342)
Cre [mg/dl]  1.2 0.7-1.3
[µmol/l] (92)
BUN [mg/dl] 38 8-23
Albumin [g/dl]  3.6 3.4-5.0
[g/l] (36)
K+ [mEq/l] 3.89 3.5-5.3
Na+ [mEq/l] 143 135-153




PO43– [mg/dl]  0.5 1.0-2.5
[mmol/l] (0.16)
Mg+2 [mEq/l] 2.0 1.3-2.1
Mgc [mEq/l] 2.2
Cl– [mEq/l] 105 98-110
UA [mg/dl] 1.7 3.5-7.2
[µmol/l] 101
Glc [mg/dl] 83 70-100
[mmol/l] 4.6
AST [U/l] 124 7-21
ALT [U/l] 24 1-21
γGT [U/l] 44 5-40
ALP [U/l] 80 32-110
CK [U/l] 72 38-174
Troponin I [ng/ml] 0.1  < 0.4
LDH [U/l] 420 50-150
FEPO43– [%] 400 < 20
FEUA [%] 68 6-12
FEK+ [%] 14 4-16
FENa+ [%] 0.29 –
e-GFR [ml/min/1.73 m2] 65 > 90
PTH [pg/ml] 52 12-68
[pmol/l] (5.5)
T Ta ab bl le e    I I. . Clinical  and  laboratory  test  results  on
admission
Hypophosphataemia in cirrhosis
chronic  hepatitis  B  virus  (HBV)  infection  and
cirrhosis 5 years ago. He was under treatment with
lamivudine 100 mg/day, amiloride 2.5 mg/day,
furosemide 20 mg/day and lactulose for 1 year. Until
then his cirrhosis had been well compensated. The
patient denies alcohol abuse in the past or currently.
On  admission,  his  blood  pressure  (BP)  was
120/75  mmHg,  pulse  rate  60/min  and  body
temperature 36°C. He had 16 breaths per minute
and an oxygen saturation of 95% while breathing
ambient air. The patient was conscious and well
oriented in time and place with no flapping tremor.
Icteric sclerae were noticed. Several spider angiomas
were present on the chest and abdomen. The
abdomen was distended and dilated veins were
present on the surface (caput medusae).
Abdominal ultrasound showed the presence of
ascites and a small irregular liver (without evidence
of hepatocellular carcinoma). Colour flow Doppler
ultrasonography  revealed  thrombus  partially
occluding the portal vein lumen. Splenomegaly was
also present. Echocardiography revealed an ejection
fraction of 60% with no signs of heart failure.
Peripheral  blood  count  revealed  moderate
anaemia with thrombocytopenia. Arterial blood gas
analysis showed pH 7.46, pCO2 38 mmHg, pO2
71 mmHg and HCO3
– 26.4 mmol/l, suggesting
mixed respiratory and metabolic alkalosis. Labora  -
tory investigation revealed severe cholestasis (total
bilirubin 50 mg/dl [855 µmol/l], direct bilirubin 
20 mg/dl [342 µmol/l]) (Table I). Serum phosphate
concentration was 0.5 mg/dl (0.16 mmol/l), while
fractional excretion of phosphate (FEPO4
3–) in urine
was 400% (normal value < 20%). There was no
evidence of hypophosphataemia-related compli  -
cations  such  as  rhabdomyolysis,  haemolysis,
respiratory  or  cardiac  failure.  Rhabdomyolysis 
is a rare manifestation of severe hypophospha  -
taemia [1]. Close monitoring for muscle-related
symptoms  as  well  as  daily  measurement  of
creatinine kinase levels are essential. Furthermore,
hypophosphataemia may affect the cardiac muscle
and lead to cardiomyopathy. In addition to a normal
echocardio  graph, creatinine kinase and troponin I
levels  were  normal  (Table  I).  Serum  calcium,
magnesium, sodium and potassium concentrations
were within normal limits (Table I). The patient also
manifested  hypouricaemia  (serum  uric  acid 
1.7 mg/dl [101 µmol/l]) with renal uric acid wasting
(Table I). Of note, glycosuria was noted in a spot urine
specimen. Urine β2 microglobulin was markedly
increased (20 mg/l [normal value < 0.3 mg/l]).
Volume of 24-h diuresis ranged from 1200 ml to
1500 ml during his hospital stay.
Serum protein electrophoresis revealed poly  -
clonal  gammopathy,  while  both serum  cerulo  -
plasmin and ferritin were within normal limits.
There was no history of heavy metal exposure.
BMI – body mass index, TBIL – total bilirubin, DBIL – direct bilirubin,
Cre  –  creatinine,  BUN  –  blood  urea  nitrogen,  K+ –  potassium, 
Na+ – sodium, Ca – total serum calcium, Cac – corrected calcium for
albumin level, PO43– – phosphate, Mg+2 – total serum magnesium,
Mg+2c – corrected magnesium for albumin level, Cl– – chloride, 
UA – uric acid, Glc – glucose, AST – aspartate aminotransferase, 
ALT  –  alanine  aminotransferase,  γGT  –  γ-glutamyl  transferase, 
ALP – alkaline phosphatase, CK – creatinine kinase, LDH – lactic
dehydrogenase, FE – fractional excretion, e-GFR – estimated glomerular
filtration rate, PTH – parathyroid hormone738 Arch Med Sci 4, August / 2011
Though hypophosphataemia in this case was
severe, there were no hypophosphataemia-related
complications. The patient was administered oral
phosphate 2000 mg per day, with careful clinical
monitoring.  Serum  phosphate  levels  reached 
2.5 mg/dl (0.8 mmol/l) in 4 days. Intravenous
phosphate administration is required for sympto  -
matic patients [1]. However, caution is needed 
since it can precipitate hypotension, severe hypo  -
calcaemia and fatal arrhythmias [1]. 
No specific treatment for partial vein occlusion
was given. He was discharged after 7 days.
Discussion
To our knowledge this is the lowest serum
phosphate level reported in a cirrhotic patient.
Hypophosphataemia  is  an  electrolyte  disorder
mainly encountered in hospitalized and critically ill
subjects [1]. In most of these cases, as also in our
patient, hypophosphataemia is of multifactorial
origin. Hypophosphataemia is causally related to
a combination of transcellular shift of phosphate
from the extracellular fluid into cells, excessive renal
phosphate  wasting  and  decreased  intestinal
phosphate absorption or poor dietary intake [1].
The marked hypophosphataemia observed in our
patient was primarily the result of increased renal
phosphate excretion, as evidenced by markedly
increased phosphate fractional excretion (Table I). 
Increased urinary excretion of phosphate is often
associated with hyperparathyroidism, either primary
or secondary [1]. However, in our patient serum
parathyroid hormone (PTH) was within normal
limits, while there was no hypercalcaemia (Table I).
The patient was not examined with dual energy 
X-ray  absorptiometry  (DEXA)  for  osteoporosis
evaluation.
Hypophosphataemia has been observed after
administration of acetazolamide, thiazide diuretics
as well as indapamide. On the other hand, loop
diuretics and amiloride have minimal effects on
phosphate metabolism [4].
Notably, hypophosphataemia in this case was
accompanied  by  hypouricaemia,  pointing  to
a proximal renal tubular defect. Indeed, renal urate
fractional  excretion  was  elevated.  In  addition,
glycosuria was noted in a spot urine specimen,
while serum glucose was within normal limits.
Furthermore, urine β2 microglobulin concentration,
which is a reliable marker of proximal renal tubular
dysfunction, was increased. It is worth mentioning
that serum potassium levels were within normal
limits in the presence of two diuretics (amiloride
and furosemide) with opposite effects on renal
potassium excretion (Table I). 
The above findings indicate a rather generalized
proximal tubular dysfunction. Fanconi’s syndrome
is the most common cause of renal phosphate
wasting  associated  with  glycosuria  and
hyperuricosuria [5]. Fanconi’s syndrome is also
associated with aminoaciduria and type 2 renal
tubular acidosis [5]. However, our patient had mixed
respiratory and metabolic alkalosis. Respiratory
alkalosis was probably due to cirrhosis-associated
hyperventilation. A superimposed metabolic alka  -
losis could be possibly due to effective circulating
volume depletion, as evidenced by low sodium
urinary excretion (FENa+ < 1%) and increased urea
nitrogen to creatinine ratio (> 20) owing to the
presence of ascites and furosemide administration.
Acquired Fanconi’s syndrome can be precipitated
by a number of agents, such as anticancer drugs,
antibiotics, antiviral agents and anticonvulsants [4].
In fact, antiviral agents used against chronic HBV
infection such as adefovir, cidofovir and tenofovir
have been implicated in this setting [4, 6]. Our
patient was receiving lamivudine, which has never
been causally related to Fanconi’s syndrome. Other
well-known causes of Fanconi’s syndrome (heavy
metal  exposure,  hereditary  disorders,  dyspro  -
teinaemias and metabolic disorders) were ruled out.
In this case generalized proximal tubular damage
seems to be causally related to jaundice. Fanconi’s
syndrome has been reported in jaundiced patients
[3]. Furthermore, Bairaktari et al. (2001) showed that
patients with obstructive jaundice had significantly
lower uric acid and phosphate levels compared with
age- and sex-matched controls [6]. However, in that
study mean serum phosphate concentration was
3.0 ±0.6 mg/dl (0.96 ±0.19 mmol/l), i.e. much
greater compared with our case [7]. The underlying
mechanisms are not fully elucidated. Bile acids may
cause oxidative damage to tubular cell membranes,
leading to the formation of oxygen free radicals 
[7-9]. Oxygen free radicals interfere with renal
handling  of  electrolytes  by  inhibiting  Na+-H+
antiport in tubular cells [8, 9].
Other factors may have also contributed to
diminished  phosphate  levels  in  our  case.
Respiratory as well as metabolic alkalosis (both
encountered in our patient) induce redistribution
of phosphate from the extracellular compartment
into the cells [1]. Additionally, in hepatic insufficiency
25 hydroxylation of vitamin D in the liver may be
impaired, thus leading to decreased synthesis of
1,25(OH)2D3 [1].  This  may  have  contributed  to
hypophosphataemia  via  decreased  phosphate
intestinal  absorption.  Unfortunately,  levels  of
1,25(OH)2D3 were not measured in our patient.
Of special consideration, protein and calorie
malnutrition, which is a common feature of chronic
liver  disease,  constitutes  a leading  cause  of
hypophosphataemia. It should be noted that even
though tubular dysfunction with impaired renal
concentration of urine β2 microglobulin has been
reported  in  deeply  jaundiced  patients  with
Elisavet Moutzouri, Evangelos N. Liberopoulos, Moses ElisafArch Med Sci 4, August / 2011 739
hepatorenal syndrome, our patient did not manifest
worsening azotemia or other signs of hepatorenal
syndrome.
In conlusion, phosphate levels should be closely
monitored in jaundiced patients, especially when
other precipitating factors are present.
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